Therefore, NK-1Rs could be considered a new therapeutic target in gliomas and NK-1R antagonists such as the drug aprepitant could be new selective, effective, and safe drugs in the treatment of gliomas such as DIPG. This evidence concerns the gene TACR1 and central nervous system cancer.